About

Our Mission

ApolloGen is dedicated to provide the most accurate and informative genetic testing services to individuals who can benefit from testing.

Our staff scientists are all experts in the field of genetic, genomics, and translational medicine. We provide expert exceptional customer service, competitive pricing, and quick turn-around time.

ApolloGen is accredited (in accordance with the U.S. Health and Human Services’ Clinical Laboratory Improvement Amendments (CLIA) of 1988 and licensed by the state of California. Please contact us if we can assist with other documentations.

CA State License: CLF 0034126 
CLIA Number: 05D2055250

ApolloGen’s tests are not direct-to-consumer. All tests must be ordered and results sent to a health care professional, usually a physician or genetic counselor. Individuals who are interested in genetic testing are encouraged contact their health care professional who can evaluate the appropriateness of genetic testing.

ApolloGen provides genetic testing services with a dedication to empower the individual to live his or her life to the fullest. We believe that genetic information should be accessible to everyone. ApolloGen offers unparalleled genetic expertise to patients and physicians. We understand the complexity and sensitivity of genetic information and are committed to ensure that testing results are communicated clearly and accurately.

If you would like to consult with a genetic counselor or medical geneticist about ApolloGen’s hereditary genetic tests or results, please contact us.

What is Genetic Testing?

DNA stands for deoxyribonucleic acid.

DNA forms your genetic material. Genes, which are made up of DNA, are the instructions to make proteins, which facilitate and control all reactions of the cell.

Therefore, DNA is the blueprint for life. Variations among individuals, from eye color to metabolism to disease susceptibility, can be attributed to the differences in DNA.

Since your DNA is inherited from your parents, there may be certain health conditions more prevalent in certain families than others by ways of inheritance. Genetic susceptibility in complicated diseases such as cancer and cardiomyopathy are often implicated in multiple genes. The genetic information locked in your genes can reveal a great deal of information for you and your family members. Collecting a good family history of the diseases seen in first-degree and second-degree relatives can help indicate risks of particulate conditions in the family, and can help your heath care professional determine whether genetic testing is recommended for you.

We understand the complexity and sensitivity of genetic information and are committed to ensure that testing results are communicated clearly and accurately.

For more actionable information on specific genetic conditions and diagnoses, please visit:

Science and Technology

ApolloGen utilizes Next-Generation Sequencing (NGS) to optimize our testing strategies for our panels.

As opposed to first generation sequencing technologies, which involve sequencing of one DNA strand at a time, NGS involves massively parallel sequencing that extends the process to millions of sequencing reactions at a time, thereby generating massive amounts of data in a short amount of time, reducing the cost of sequencing significantly. The introduction of NGS technology has prompted a substantial transformation in the capability of gene sequencing in clinical settings. Gene sequencing is becoming an increasingly integral part of preventative healthcare and personalized health management.

Identifying mutations using this technology involves four steps:

  1. preparation of a complete genomic library from the patient’s genomic DNA (gDNA),
  2. enrichment of that library for predefined protein coding regions,
  3. next-generation sequencing of the enriched library and
  4. sequencing read alignment and quality control. At that point the test is ready for interpretation using the bioinformatics pipeline.

The patient’s genomic DNA is extracted and direct sequencing of the enriched targeted regions is performed. NGS uses mass parallel sequencing technique to enhance the resolution, throughput, and speed of sequencing. The patient’s gene sequences are then compared to a standard reference sequence and appropriate locus-specific databases. Detected variants are referenced to reports in the scientific literature to determine pathogenicity. Depending on the coverage criteria of each panel, capillary sequencing is used to confirm all potentially pathogenic variants identified by sequencing and to fill in low coverage regions of the targeted exons. NGS sequencing does not interrogate the promoter region, deep intronic regions, or other regulatory elements of the gene, and does not detect single or multi-exon deletions or duplications.

I'm a Health Care Provider
interested in genetic testing

order a test
visitor